The present invention relates to aspartic protease inhibitors represented by the following structural formula (I), or a pharmaceutically acceptable salt thereof. The present invention is also directed to pharmaceutical compositions comprising the aspartic protease inhibitors of Structural Formula (I). The invention also discloses methods of antagonizing one or more aspartic proteases in a subjectin need thereof, and methods for treating an aspartic protease mediated disorder in a subject using these aspartic protease inhibitors.